← FDA DRUG APPROVALS

FDA ANDA · ANDA074650

SULFAMETHOXAZOLE AND TRIMETHOPRIM

Sponsor: HIKMA

APPLICATION
ANDA074650
TYPE
ANDA
ORIGINAL APPROVAL
1997-12-29
LATEST ACTION
2025-02-21
ROUTE
ORAL
DOSAGE FORM
SUSPENSION
MARKETING STATUS
Discontinued

Products

SULFAMETHOXAZOLE AND TRIMETHOPRIMDiscontinued
SULFAMETHOXAZOLE 200MG/5ML, TRIMETHOPRIM 40MG/5ML · SUSPENSION · ORAL

Approval history

2025-02-21Labeling · Supplement 24 · standardAP
2024-06-24Labeling · Supplement 22 · standardAP
2022-07-06Labeling · Supplement 19 · standardAP
2014-12-24Manufacturing (CMC) · Supplement 12AP
2011-12-15Labeling · Supplement 10LabelAP
2009-09-15Labeling · Supplement 8AP
2000-04-21Manufacturing (CMC) · Supplement 4AP
2000-01-24Manufacturing (CMC) · Supplement 1AP
2000-01-24Labeling · Supplement 2AP
1997-12-29OriginalReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →